Early-onset Cardiotoxicity Assessment Related to Anthracycline in Children with Leukemia. A Prospective Study

Overview

Journal Colomb Med (Cali)

Specialties General Medicine
Public Health

Date 2021 Apr 29

PMID 33911320

Citations 3

Authors

Adriana Linares Ballesteros

Roy Sanguino Lobo

Juan Camilo Villada Valencia

Oscar Arevalo Leal

Diana Constanza Plazas Hernandez

Nelson Aponte Barrios

Ivan Perdomo Ramirez

Affiliations

Soon will be listed here.

Abstract

Background: Acute leukemias are the most frequent malignancies in children. Advances in treatment have improved the overall survival to 80%. Almost 10% of children with cancer develop clinical cardiac toxicity. Total anthracycline cumulative dose is a risk factor for early-onset cardiotoxicity.

Objective: To describe the incidence of early-onset cardiotoxicity in children with acute leukemia treated with chemotherapy.

Methods: A prospective descriptive study of patients >1 y and <18 years diagnosed with acute leukemia. Assessed with electrocardiograma, echocardiography, and blood biomarkers at diagnosis and during the follow-up.

Results: 94 patients with acute lymphoblastic leukemia and 18 with acute myeloid leukemia were included. 20 patients (17.9%) developed early-onset cardiotoxicity. Statistically significant data was seen after anthracycline dose >150 mg/m, between the first echocardiographic evaluation and posterior analyses in the left ventricular fraction ejection with Teicholz 0.05, Simpson 0.018 and GLS 0.004. In this study, there was no relation between blood biomarkers and cardiotoxicity.

Conclusions: Cancer therapeutic-related cardiac dysfunction is related to anthracycline cumulative dose. In this study, echocardiographic follow-up was useful to predict risk factors for early cardiac dysfunction.

Citing Articles

Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review.

Kouwenberg T, van Dalen E, Feijen E, Netea S, Bolier M, Slieker M BMC Cancer. 2023; 23(1):866.

PMID: 37710224 PMC: 10500898. DOI: 10.1186/s12885-023-11353-9.

Correlating decline in left ventricular ejection fraction and longitudinal strain in pediatric cancer patients.

Sanchez Mejia A, Pignatelli R, Rainusso N, Lilje C, Sachdeva S, Tunuguntla H Int J Cardiovasc Imaging. 2022; 39(4):747-755.

PMID: 36543913 DOI: 10.1007/s10554-022-02780-z.

Cardiotoxicity in cancer patients treated with chemotherapy: A systematic review.

Lima M, Brito H, Mitidieri G, de Souza E, Sobral A, Melo H Int J Health Sci (Qassim). 2022; 16(6):39-46.

PMID: 36475028 PMC: 9682875.

References

Bansal N, Blanco J, Sharma U, Pokharel S, Shisler S, Lipshultz S . Cardiovascular diseases in survivors of childhood cancer. Cancer Metastasis Rev. 2020; 39(1):55-68. PMC: 7123498. DOI: 10.1007/s10555-020-09859-w. View

Bansal N, Amdani S, Hutchins K, Lipshultz S . Cardiovascular disease in survivors of childhood cancer. Curr Opin Pediatr. 2018; 30(5):628-638. DOI: 10.1097/MOP.0000000000000675. View

Oikonomou E, Kokkinidis D, Kampaktsis P, Amir E, Marwick T, Gupta D . Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA Cardiol. 2019; 4(10):1007-1018. PMC: 6705141. DOI: 10.1001/jamacardio.2019.2952. View

Sieswerda E, Postma A, van Dalen E, van der Pal H, Tissing W, Rammeloo L . The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol. 2012; 23(8):2191-2198. DOI: 10.1093/annonc/mdr595. View

Steliarova-Foucher E, Colombet M, Ries L, Moreno F, Dolya A, Bray F . International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017; 18(6):719-731. PMC: 5461370. DOI: 10.1016/S1470-2045(17)30186-9. View

Cardinale D, Colombo A, Sandri M, Lamantia G, Colombo N, Civelli M . Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114(23):2474-81. DOI: 10.1161/CIRCULATIONAHA.106.635144. View

Kim H, Kang H, Park K, Koh K, Im H, Seo J . Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients. Cancer Res Treat. 2018; 51(1):357-367. PMC: 6333985. DOI: 10.4143/crt.2017.457. View

Mavinkurve-Groothuis A, Groot-Loonen J, Marcus K, Bellersen L, Feuth T, Bokkerink J . Myocardial strain and strain rate in monitoring subclinical heart failure in asymptomatic long-term survivors of childhood cancer. Ultrasound Med Biol. 2010; 36(11):1783-91. DOI: 10.1016/j.ultrasmedbio.2010.08.001. View

Dolci A, Dominici R, Cardinale D, Sandri M, Panteghini M . [Biochemical markers for predicting chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use]. G Ital Cardiol (Rome). 2006; 7(9):604-11. View

10.

Reichardt P, Tabone M, Mora J, Morland B, Jones R . Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018; 14(25):2663-2676. DOI: 10.2217/fon-2018-0210. View

11.

Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N . Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010; 28(8):1308-15. DOI: 10.1200/JCO.2008.20.2267. View

12.

Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S . Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2013; 32(3):174-84. DOI: 10.1200/JCO.2013.48.6522. View

13.

Harake D, Franco V, Henkel J, Miller T, Lipshultz S . Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol. 2012; 8(4):647-70. PMC: 3870660. DOI: 10.2217/fca.12.44. View

14.

Lipshultz S, Lipsitz S, Sallan S, Dalton V, Mone S, Gelber R . Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23(12):2629-36. DOI: 10.1200/JCO.2005.12.121. View

15.

Mavinkurve-Groothuis A, Marcus K, Pourier M, Loonen J, Feuth T, Hoogerbrugge P . Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging. 2012; 14(6):562-9. DOI: 10.1093/ehjci/jes217. View

16.

Hildebrandt M, Reyes M, Wu X, Pu X, Thompson K, Ma J . Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors. Sci Rep. 2017; 7(1):9698. PMC: 5575079. DOI: 10.1038/s41598-017-09517-2. View

17.

Armenian S, Hudson M, Mulder R, Chen M, Constine L, Dwyer M . Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015; 16(3):e123-36. PMC: 4485458. DOI: 10.1016/S1470-2045(14)70409-7. View

18.

Leger K, Slone T, Lemler M, Leonard D, Cochran C, Bowman W . Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatr Blood Cancer. 2014; 62(1):123-7. DOI: 10.1002/pbc.25206. View

19.

Feijen E, Leisenring W, Stratton K, Ness K, van der Pal H, van Dalen E . Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncol. 2019; 5(6):864-871. PMC: 6490232. DOI: 10.1001/jamaoncol.2018.6634. View

20.

Kocabas A, Kardelen F, Ertug H, Aldemir-Kocabas B, Tosun O, Yesilipek A . Assessment of early-onset chronic progressive anthracycline cardiotoxicity in children: different response patterns of right and left ventricles. Pediatr Cardiol. 2013; 35(1):82-8. DOI: 10.1007/s00246-013-0745-x. View